SNC-106

N/A

Report date: 2025/01/26 16:59:15

Base Information

Drug NameSNC-106
Drug Alias Nameanti-HPV TCR T-cell therapy (Shanghai Simnova)SNC-106
ClassificationBiologics > Protein drugs > Recombinant proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionHuman leukocyte antigen modulators
TargetsHuman leukocyte antigen
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesShanghai Simnova Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Simnova Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A